Interline Therapeutics has technology that shows how proteins interact as communities, paving the way for the discovery of new drugs. CEO Zachary Sweeney, a Denali Therapeutics veteran, said the startup will use the $92 million in funding to advance programs in cancer and inflammatory diseases.
Read about news from Seven Bridges, Outcomes4Me, Carrum Health and more.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
Cue Health, a startup developing a connected testing device, closed a $100 million series C round. The company recently submitted its system to the FDA for emergency use authorization to be used for onsite Covid-19 testing.
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The venture firm primarily invests in biotech startups. It has $650 million in assets under management, not including this supposed $450 million round.